Phase 2 Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced new non-dilutive external funding, additional to the previously announced U.S. Government funding, which now covers the entirety of the RHB-107 (upamostat) arm of the ACESO PROTECT adaptive platform trial for early COVID-19 outpatient treatment. This additional funding amounts to approximately $4.8M directed towards evaluation of RHB-107 in the PROTECT study.

Microbion Corporation today announced that the company will be presenting a poster that highlights key clinical study design elements from an ongoing phase 2 study assessing safety and efficacy of topical pravibismane in subjects suffering from moderate infections associated with chronic diabetic foot ulcers at the 2023 Military Health System Research Symposium being held from August 14th to 17th, 2023, at the Gaylord Palms Resort and Convention Center in Kissimmee, FL. This Phase 2 study is fun

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that its subsidiary Algernon NeuroScience (AGN Neuro), has completed a feasibility study and has finalized its clinical trial design for a 40 patient Phase 2 DMT Stroke study. AGN Neuro is the world’s first company to investigate DMT for the tre

RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RHB-107 (upamostat)3 has been accepted for inclusion in the Austere environments Consortium for Enhanced Sepsis Outcomes' (ACESO) U.S. Government-supported PROTECT multinational platform trial for early COVID-19 outpatient treatment to be conducted in the U.S., Thailand, Ivory Coast and South Africa. The Company also announced that the Phase 2 study, predominantly funde

COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative...